Redox cofactor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-16. Numbers and descriptions here follow the published literature rather than marketing material.
Beyond redox chemistry, NAD+ is consumed as a substrate by enzymes that transfer ADP-ribose or remove acetyl groups. Sirtuins use NAD+ in deacylation reactions, poly(ADP-ribose) polymerases use it in DNA damage responses, and CD38 hydrolases convert it to signaling metabolites. Because these enzymes compete for the same pool, changes in NAD+ availability can influence multiple cellular processes. The relative contribution of each consumption route differs by cell type and condition, and precise quantitative links remain an active area of study.
Research on NAD+ spans biochemistry, aging biology, and metabolism. Studies often examine how NAD+ levels change with age, diet, exercise, or disease states, and whether precursor supplementation alters those levels. Findings in animal models do not automatically translate to humans, and measurement methods vary across studies. Questions about tissue-specific effects, long-term consequences, and causal relationships remain open. NAD+ itself is not established as a single therapeutic agent with a broad clinical role.
NAD+ also serves as a substrate for enzymes that cleave it, including sirtuins, PARPs, and CD38. These enzymes consume NAD+ and release nicotinamide and ADP-ribose or related products. The dual roles as redox cofactor and signaling substrate connect NAD+ to DNA repair, circadian regulation, and calcium signaling. Cellular NAD+ concentrations vary by tissue, time of day, and stress exposure. How these consumption pathways interact with redox balance remains an active area of research.
NAD+ is a dinucleotide composed of two nucleotides joined by a pyrophosphate linkage. One nucleotide contains adenine, and the other contains nicotinamide. The oxidized form carries a positive charge on the nicotinamide ring and is abbreviated NAD+. It functions as a cofactor in hydride-transfer reactions, accepting electrons in catabolic pathways. In cells, it interconverts with reduced NADH, forming a redox couple central to energy metabolism. The molecule is water-soluble and does not cross cell membranes freely without specific transport or precursor pathways.
The nicotinamide ring undergoes reversible reduction at the para position, converting NAD+ to NADH. This reaction transfers a hydride equivalent, not a free hydrogen atom or electron alone. Because the redox pair has a defined reduction potential, it links oxidation of fuels to respiratory chain activity. Many dehydrogenases use NAD+ as a co-substrate and produce NADH. The ratio of NAD+ to NADH reflects metabolic state and influences flux through several pathways.
| Property | Value | Notes |
|---|---|---|
| Chemical formula | C21H27N7O14P2 | Free acid form; salt and hydrate forms differ in mass. |
| Molar mass | 663.43 g/mol | Anhydrous free acid; counterions and water change the value. |
| Appearance | White to off-white powder | Typical solid reagent; exact color varies by purity and form. |
| Solubility class | Highly water-soluble | Aqueous solutions are acidic; organic solubility is generally limited. |
| Common synonyms | DPN, coenzyme I, NAD | Older literature often uses diphosphopyridine nucleotide or DPN. |
In glycolysis, NAD+ accepts electrons during the oxidation of glyceraldehyde-3-phosphate, forming NADH. The tricarboxylic acid cycle and fatty acid oxidation also generate NADH, which donates electrons to the mitochondrial electron transport chain. This flow supports ATP synthesis and helps maintain the redox balance of the cell. Other dehydrogenases use NAD+ as a cofactor for biosynthetic reductions and detoxification reactions. NADH is later reoxidized to sustain continued flux through these pathways.
Beyond electron transfer, NAD+ serves as a substrate for enzymes that cleave the molecule and transfer ADP-ribose units. Sirtuins, poly(ADP-ribose) polymerases, and CD38 consume NAD+ in regulatory reactions. These activities link NAD+ availability to DNA repair, chromatin modification, calcium signaling, and metabolic stress responses. Because consumption can exceed biosynthesis under some conditions, cellular NAD+ levels are dynamic rather than fixed. Enzyme affinity and local synthesis also influence how much NAD+ is available for signaling.
NAD+ stands for nicotinamide adenine dinucleotide, the oxidized form of a coenzyme found in all living cells. The molecule consists of two nucleotides, adenine and nicotinamide ribose, joined through phosphate groups. Its chemical formula is C21H27N7O14P2, and the free acid has a molar mass near 663.43 grams per mole. In redox reactions, NAD+ accepts a hydride ion and becomes NADH. The pair NAD+ and NADH participates in hundreds of metabolic reactions, including steps in glycolysis, the citric acid cycle, and oxidative phosphorylation.
In cells, NAD+ functions primarily as an electron carrier. Dehydrogenase enzymes in glycolysis and the citric acid cycle transfer hydride from substrates to NAD+, producing NADH. NADH then delivers electrons to the mitochondrial respiratory chain, supporting ATP synthesis. In fermentation, NADH is reoxidized to NAD+ so that glycolysis can continue. The balance between NAD+ and NADH helps set metabolic flux. Beyond redox, NAD+ serves as a substrate for enzymes that cleave it, including sirtuins, poly(ADP-ribose) polymerases, and CD38. These reactions consume NAD+ and release nicotinamide and ADP-ribose products.
=== Pregnancy and lactation === Experimental animal studies did not indicate injurious effects of opipramol on the embryonic development or fertility. Opipramol should only be prescribed during pregnancy, particularly in the first trimester, for compelling indication. It should not be used during lactation and breastfeeding, since it passes into breast milk in small quantities.
== History == Gemtuzumab ozogamicin was created in a collaboration between Celltech and Wyeth that began in 1991. The same collaboration later produced inotuzumab ozogamicin. Celltech was acquired by UCB in 2004 and Wyeth was acquired by Pfizer in 2009. In the United States, gemtuzumab ozogamicin was approved under an accelerated-approval process by the FDA in 2000, for use in patients over the age of 60 with relapsed acute myelogenous leukemia (AML); or those who are not considered candidates for standard chemotherapy. The accelerated approval was based on the surrogate endpoint of response rate. It was the first antibody-drug conjugate to be approved. Within the first year after approval, the FDA required a black box warning be added to gemtuzumab packaging. The drug was noted to increase the risk of veno-occlusive disease in the absence of bone marrow transplantation. Later the onset of VOD was shown to occur at increased frequency in gemtuzumab patients even following bone marrow transplantation. The drug was discussed in a 2008 JAMA article, which criticized the inadequacy of postmarketing surveillance of biologic agents. A randomized Phase III comparative controlled trial (SWOG S0106) was initiated in 2004, by Wyeth in accordance with the FDA accelerated-approval process. The study was stopped on August 20, 2009, prior to completion due to worrisome outcomes. Among the patients evaluated for early toxicity, fatal toxicity rate was significantly higher in the gemtuzumab combination therapy group vs the standard therapy group.
21st International Symposium on Chirality STEREOISOMERISM - OPTICAL ISOMERISM Symposium highlights-Session 5: New technologies for small molecule synthesis IUPAC nomenclature for amino acid configurations. Michigan State University's explanation of R/S nomenclature Chirality & Odour Perception at leffingwell.com Chirality & Bioactivity I.: Pharmacology Chirality and the Search for Extraterrestrial Life "The Handedness of the Universe" by Roger A Hegstrom and Dilip K Kondepudi, Scientific American, January 1990
Within days of the Alvor Agreement, the Central Intelligence Agency launched its own programme, Operation IA Feature, to arm the FNLA, with the stated objective of "prevent[ing] an easy victory by Soviet-backed forces in Angola". The United States was searching for regional allies to take part in Operation IA Feature and perceived South Africa as the "ideal solution" in defeating the pro-Soviet MPLA. With tacit American encouragement, the FNLA and UNITA began massing large numbers of troops in northern and southern Angola, respectively, in an attempt to gain tactical superiority. The transitional government installed by the Alvor Agreement disintegrated and the MPLA requested support from its communist allies. Between February and April 1975, the MPLA's armed wing, the People's Armed Forces of Liberation of Angola (FAPLA), received shipments of Soviet arms, mostly channelled through Cuba or the People's Republic of the Congo. At the end of May, FAPLA personnel were being instructed in their use by a contingent of about 200 Cuban military advisers. Over the next two months, they proceeded to inflict a series of crippling defeats on the FNLA and UNITA, which were driven out of the Angolan capital, Luanda.
Morpholino Also phosphorodiamidate Morpholino oligomer. A synthetic nucleic acid analogue connecting a short sequence of nucleobases into an artificial antisense oligomer, used in genetic engineering to knockdown gene expression by pairing with complementary sequences in naturally occurring RNA or DNA molecules, especially mRNA transcripts, thereby inhibiting interactions with other biomolecules such as proteins and ribosomes. Morpholino oligomers are not themselves translated, and neither they nor their hybrid duplexes with RNA are attacked by nucleases; also, unlike the negatively charged phosphates of normal nucleic acids, the synthetic backbones of Morpholinos are electrically neutral, making them less likely to interact non-selectively with a host cell's charged proteins. These properties make them useful and reliable tools for artificially generating mutant phenotypes in living cells.
Sources: en.wikipedia.org
Per- and Polyfluoroalkyl Substances (PFAS) at the National Toxicology Program Per- and Polyfluoroalkyl Substances and Your Health at the Agency for Toxic Substances and Disease Registry Per- and Polyfluoroalkyl Substances (PFAS) at the EPA Per- and polyfluoroalkyl substances (PFASs) at the European Chemicals Agency PFAS contamination map of Europe Per- and Polyfluoroalkyl substances, National Institute for Occupational Safety and Health The Forever Pollution Project – Journalists tracking PFAS across Europe PFAS contamination in Queensland, Australia, State Library of Queensland "Contaminated: The Carpet Industry's Toxic Legacy". Frontline. Season 44. Episode 8. 3 February 2026. PBS. WGBH. Retrieved 25 February 2026.
=== Shwachman–Diamond syndrome === Shwachman–Diamond syndrome (SDS) is caused by bi-allelic mutations in the SBDS protein that affects its ability to couple GTP hydrolysis by the GTPase EFL1 to the release of eIF6 from the 60S subunit. Clinically, SDS affects multiple systems, causing bony abnormalities, and pancreatic and neurocognitive dysfunction. SBDS associates with the 60S subunit in human cells and has a role in subunit joining and translational activation in yeast models.
This is a list of investigational anxiety disorder drugs, or drugs that are currently under development for clinical use in the treatment of anxiety disorders (type unspecified) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]". This list was last comprehensively updated in September 2025. It is likely to become outdated with time.
=== Pain modulation === Like other dynorphin peptides, big dynorphin can produce analgesic effects through κ-opioid receptor (KOR) activation at spinal nociceptive sites. However, at supraspinal levels through non-opioid mechanisms involving NMDA receptor modulation and ASIC1a activation, big dynorphin can produce pro-nociceptive effects, enhancing pain sensitivity in both acute and chronic pain states.
Sources: en.wikipedia.org
NAD+ is a coenzyme found in all living cells. It carries electrons in metabolic reactions and also serves as a substrate for enzymes involved in signaling and DNA repair. Its oxidized and reduced forms are central to energy metabolism.
NAD+ is the oxidized form and NADH is the reduced form. The pair accepts and donates electrons in redox reactions. Their ratio helps indicate the metabolic state of a cell or compartment.
No. Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are precursors that cells can convert into NAD+. They are distinct molecules with different absorption and metabolism profiles.
NAD+ is the oxidized form, while NADH is the reduced form carrying an added hydride. The two form a redox pair that cells use in many energy-yielding reactions.